1 Durable reprogramming of neutralising antibody

2 responses following breakthrough Omicron infection

3 Wen Shi Lee^{1†}, Hyon-Xhi Tan^{1†}, Arnold Reynaldi², Robyn Esterbauer¹, Marios Koutsakos¹, Julie Nguyen¹, Thakshila Amarasena¹, Helen E Kent¹, Anupriya 4 Aggarwal², Stuart G Turville², George Taiaroa³, Paul Kinsella³, Kwee Chin Liew³, 5 Thomas Tran³, Deborah A Williamson^{3,4}, Deborah Cromer², Miles P Davenport², 6 Stephen J Kent^{1,5}, Jennifer A Juno¹, David S Khoury², Adam K Wheatley^{1*} 7 8 ¹Department of Microbiology and Immunology, University of Melbourne, Peter 9 Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. 10 11 ²Kirby Institute, University of New South Wales, Kensington, New South Wales, 12 Australia ³Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital 13 14 at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia ⁴Department of Infectious Diseases, The University of Melbourne at the Peter 15 16 Doherty Institute for Infection and Immunity, Victoria, 3000, Australia ⁵Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred 17 18 Hospital and Central Clinical School, Monash University, Melbourne, Victoria, 19 Australia 20

- [†]Contributed equally
- 22 *Corresponding author: <u>a.wheatley@unimelb.edu.au</u>
- 23

24 Abstract

25 SARS-CoV-2 breakthrough infection of vaccinated individuals is increasingly 26 common with the circulation of highly immune evasive and transmissible Omicron 27 variants. Here, we report the dynamics and durability of recalled spike-specific 28 humoral immunity following BA.1 or BA.2 breakthrough infection, with longitudinal 29 sampling up to 8 months post-infection. Both BA.1 and BA.2 infection robustly 30 boosted neutralisation activity against the infecting strain while expanding breadth 31 against other Omicron strains. Cross-reactive memory B cells against both ancestral 32 and Omicron spike were predominantly expanded by infection, with limited

33	recruitment of de novo Omicron-specific B cells or antibodies. Modelling of
34	neutralisation titres predicts that protection from symptomatic reinfection against
35	antigenically similar strains will be remarkably durable, but is undermined by novel
36	emerging strains with further neutralisation escape.
37	

38 One sentence summary

39 Omicron breakthrough infection elicits durable neutralising activity by recalling cross-

40 reactive vaccine-elicited memory B cells.

41 Introduction

42 SARS-CoV-2 continues to cause significant morbidity and mortality. While currently 43 licensed vaccines based on the ancestral strain of SARS-CoV-2 (Wuhan-Hu-1) are 44 effective at preventing severe COVID-19, they have reduced effectiveness at 45 preventing infection with novel variants that escape vaccine-elicited neutralising 46 antibodies. The Omicron variant is highly antigenically distinct and rapidly 47 outcompeted the Delta variant to become the dominant global strain in early 2022. 48 Various sub-lineages of Omicron (BA.1, BA.2, BA.4, BA.5 and others), each with 49 different degrees of antibody evasion, have since emerged in successive waves (1, 50 2). The high transmissibility and immune evasion of Omicron, in tandem with waning 51 of vaccine-elicited immunity, have resulted in increasing frequencies of 52 "breakthrough" infections of vaccinated individuals. At a population level, immunity 53 against SARS-CoV-2 is thus becoming increasingly complex, with variable dosing 54 and types of vaccines, infection with distinct variants, or a combination of both 55 (hybrid immunity).

56

57 Recent studies of antibody and memory B cell responses following breakthrough 58 infection with Delta or Omicron BA.1 have established rapid anamnestic recall of 59 spike-specific antibody responses, reactivation of spike-specific memory B cells and 60 differentiation of antibody-secreting cells (3-5). Breakthrough Omicron infection in 61 individuals with 2 prior vaccine doses has also been associated with increases in the 62 breadth of serum neutralising antibody activity compared to those receiving a third 63 dose of vaccine (3, 6). Increased neutralising breadth could be derived from de novo 64 antibody responses against neo-epitopes within Omicron spike, or alternatively the 65 selective re-expansion of cross-reactive memory B cells established during

66 vaccination. Here we intensively examined the early kinetics of recalled immunity 67 following Omicron BA.1 or BA.2 breakthrough infections, as well as profiled the 68 durable changes in serological neutralisation breadth following recovery. We find that 69 breakthrough infections, despite mild disease course, were highly efficient at both 70 recalling spike-specific memory responses established by prior immunisation, as well 71 as generating novel responses to the viral nucleocapsid. While BA.1 or BA.2 72 neutralising titres were low or undetectable at early timepoints following infection, 73 these responses expanded robustly and demonstrated breadth against the more 74 escaped BA.4 variant. Longitudinal follow up revealed remarkably stable 75 maintenance of Omicron-specific neutralising activity, which we then modelled to 76 estimate the protective window against reinfection with the same or novel variants 77 with further immune escape. Understanding the impact of periodic infection with 78 increasingly distinct SARS-CoV-2 variants upon the durability and breadth of 79 antibody and memory B cell immunity will be critical to informing optimal design and 80 deployment of COVID-19 vaccines to maximise population-level protection against 81 future variants.

83 **Results**

84 BA.1 or BA.2 breakthrough infection drives high viral loads and is 85 immunogenic despite mild disease course

86 Twenty-six vaccinated individuals (3 with two prior vaccines, 21 with three prior 87 vaccines and 2 previously infected with ancestral virus and subsequently vaccinated) 88 were recruited following Omicron breakthrough infection that occurred at a median of 89 95 days (IQR 78-124) after receiving their last COVID vaccine dose (Table S1). All 90 individuals reported a mild but symptomatic disease course. Omicron BA.1 infection 91 was confirmed using whole genome sequencing for 8 individuals, and BA.2 92 confirmed for 15 individuals, with the remaining presumptively designated BA.1 (2) 93 individuals) or BA.2 (1 individual) infections based on the prevalent variants 94 circulating at the time. Serial blood samples and nasal swabs were obtained up to 95 247 days of follow up, with intensive sampling during the acute infection phase 96 (Figure 1A).

97

98 SARS-CoV-2 viral load in nasal swabs was measured via qPCR of the nucleocapsid 99 (N) gene (Figure 1B). Omicron BA.1 and BA.2 breakthrough infection showed similar 100 viral kinetics, with most individuals displaying peak viral load upon recruitment at 101 around 1-3 days post-symptom onset. Median peak Ct values were consistent with 102 previous reports demonstrating robust viral replication during Omicron breakthrough 103 infection despite prior immunisation (7, 8). 19 of 21 individuals in our cohort had no 104 prior documented COVID-19 infection and were immunised with COVID-19 vaccines 105 encoding only the spike antigen (BNT162b2, ChAdOx1 nCoV-19, mRNA-1273, NVX-106 CoV2373) (Table S1). Supporting this, serological responses against SARS-CoV-2 N 107 were at low or undetectable levels at the earliest timepoints sampled (Figure 1C).

However, a clear and consistent expansion of N-specific IgG was observed in plasma samples from ~7 days post-symptom onset, with similar trajectories for both BA.1 and BA.2 breakthrough infection (Table S2). Overall, individuals with Omicron breakthrough infection in our cohort exhibited marked viral replication in the upper respiratory tract and seroconverted to N.

113

114 Durable boosting of neutralising antibody responses following BA.1 or BA.2

115 breakthrough infection

116 At the earliest sampled timepoint following infection (<5 days post-symptom onset). 117 the majority of subjects had robust serological neutralisation activity against 118 ancestral SARS-CoV-2 virus (VIC01), but low or undetectable neutralisation titres 119 against BA.1 or BA.2 (Figure 2A). Neutralising titres against the ancestral strain were 120 rapidly recalled by infection, starting from day 3-4 onwards and concomitant with 121 rises in neutralisation activity against the matched infecting strain. One BA.1-infected 122 individual (CP69) had a transient rise in BA.1 neutralisation activity from days 9-21, 123 before waning to undetectable levels at day 44 post-symptom onset. However, in all 124 other subjects, recovery from infection was associated with robust boosting of BA.1 125 or BA.2 plasma neutralisation activity.

126

We applied a piecewise linear regression model to parameterise the kinetics of antibody recall, including estimates of the initial period of delay, the rate of increase, and time to maximal titres (Table S3). The initial delay phase before detectable increases in neutralising activity against the homologous infecting strain was similar between BA.1 or BA.2 infected subjects, at 3.1 and 3.6 days respectively, with a doubling time of 2.1 and 2.8 days thereafter. Robust expansion of BA.1 and BA.2

neutralising activity against the infecting homologous strains was observed in both
BA.1 and BA.2 infected cohorts (31- and 34.7-fold respectively), contrasting with the
more modest rise of neutralising activity against VIC01 (5.4- and 15.6-fold
respectively).

137

138 We next examined the breadth of neutralising antibody responses following 139 breakthrough infection with a panel of Omicron variants including the more immune 140 evasive BA.4 variant. At around 1-month post-symptom onset (median 34 days, IQR 141 28.5-36.5), individuals with BA.1 breakthrough infection had median neutralisation 142 titres of 1188 against VIC01, 190 against BA.1, 316 against BA.2 and 176 against 143 BA.4 while individuals with BA.2 breakthrough infection had median titres of 5038 144 against VIC01, 616 against BA.1, 1468 against BA.2 and 936 against BA.4 (Figure 145 2B). The degree of escape relative to ancestral virus was consistent between the two 146 cohorts, at ~6-fold for BA.1, ~4-fold for BA.2 and ~6-fold for BA.4. Neutralising titres 147 were consistently higher in subjects with BA.2 breakthrough infection, however this is 148 likely reflective of higher baseline titres in these individuals rather than any 149 differential immunogenicity between BA.1 and BA.2.

150

The longevity of neutralising antibody responses following breakthrough infection was examined in a subset of BA.1-infected (n=7, days 167-247) and BA.2-infected subjects (n=8, days 80-155) (Table S1). After BA.1 infection, BA.1 neutralising titres were stably maintained and readily detectable 5-8 months post-infection, with a halflife of 334 days (Figure 2C, Table S4). An exception was a single subject (CP69) who did not have detectable titres after day 44. Neutralisation against ancestral VIC01 decayed at a half-life of 183 days and remained high (>1:1000) for all

individuals at the late timepoint. Durable BA.2-specific neutralising responses were similarly observed in BA.2-infected subjects, with a half-life of 1050 days. Notably, 4 out of 8 BA.2-infected individuals exhibited an increase in neutralising activity between early and late timepoints, indicating that peak titres may have occurred more than 1-month post-symptom onset (Figure 2C, Table S4). Neutralisation against ancestral VIC01 virus was comparably durable and maintained over the 3–4month period, with a half-life of 1216 days.

165

166 *Omicron BA.1 and BA.2 breakthrough infection recalls antibodies that are* 167 *predominantly cross-reactive against ancestral SARS-CoV-2 spike*

168 Robust and broad neutralising responses against Omicron strains following 169 breakthrough infection could derive from recalled immunological memory or 170 comprise de novo BA.1 or BA.2-specific antibodies. We pre-incubated plasma 171 samples with Wuhan-Hu-1 spike or a BSA control to sequester antibodies that bind 172 to ancestral spike, and probed for residual binding activity against BA.1 or BA.2 173 spike by IgG ELISA. In plasma samples taken during the first week post-symptom 174 onset, pre-incubation with ancestral spike eliminated any residual biding to the BA.1 175 and BA.2 spike, with no evidence for omicron-specific reactivity (Figure 2D). 176 However, after recovery (~1-month post-symptom onset), low titres of antibodies 177 specific for BA.1 alone were detected in 3 of 8 individuals. In contrast, no BA.2-178 infected subjects had antibodies specific for BA.2 alone. This demonstrates that 179 antibody responses to BA.1 and BA.2 breakthrough infection is dominated by cross-180 reactive specificities that also bind to ancestral spike.

181

182 Omicron BA.1 and BA.2 breakthrough infection primarily recalls memory B

183 cells cross-reactive with ancestral SARS-CoV-2 spike

184 In individuals with prior SARS-CoV-2 immunity established by ancestral spike 185 vaccines, Omicron breakthrough infection could potentially broaden the memory B 186 cell repertoire by eliciting B cells against neo-epitopes within Omicron spike. We 187 therefore examined the recall of cross-reactive spike-specific memory B cells 188 established primarily through prior vaccination or the elicitation of de novo Omicron-189 specific memory B cells. Spike-specific memory B cells within PBMC samples were 190 stained using a combination of fluorescent spike probes (ancestral Wuhan Hu-1 191 spike in combination with either BA.1 or BA.2 spike; gating in Figure S1). We 192 observed substantial expansion of class-switched memory B cells (CD19+ IgD-) that 193 were cross-reactive to SARS-CoV-2 ancestral spike and BA.1/BA.2 spike (Figure 194 3A). Frequencies of cross-reactive memory B cells peaked around 1-month post-195 symptom onset, before subsequently waning over 100 days of follow up (Figure 3B). 196 We did not observe notable expansion of monospecific memory B cells against 197 either BA.1 or BA.2 Spike (Figure 3A). BA.1 and BA.2 monospecific memory B cells 198 were on average 7 and 16-fold lower than their cross-reactive counterparts around 1-199 month post-symptom onset, with frequencies remaining unchanged throughout the 200 longitudinal sampling period (Figure 3B).

201

A large proportion of cross-reactive memory B cells exhibited an activated phenotype (CD21- CD27+) in PBMC samples taken ~day 10 post-symptom onset (median 58%), indicating efficient antigen recall during Omicron breakthrough infection, which later waned over the course of recovery (median 14% at ~day 160) (Figure 3C). We observed a distinct lack of activation of BA.1 or BA.2 monospecific memory B cells,

207 suggesting these cells likely represent background binding or B cells with low affinity 208 for spike (Figure 3C). Cross-reactive memory B cells were predominantly IgG+ at all 209 timepoints, with minor subpopulations of IqA+ or IqM+ isotypes (Figure 3D). In 210 contrast, 45-60% of BA.1/BA.2 monospecific memory B cells were IgG+, which 211 remained relatively unchanged after breakthrough infection, suggesting limited 212 exposure to antigen in vivo. Overall, our data suggests that the cross-reactive 213 memory B cells predominates the recall response, with Omicron-specific populations 214 remaining unexpanded, following Omicron breakthrough infection.

215

Estimated protection against reinfection following breakthrough infection is robust but moderated by immune escape

218 The immunity gained at a population level via breakthrough infection remains unclear. 219 Using the previously developed model for predicting protection from symptomatic 220 infection based on neutralisation titres (9), we estimated the durability of protection 221 following Omicron breakthrough infection (Figure 4A, 4B). Since decay rates of 222 neutralising antibodies against the infecting strains were not significantly different 223 across BA.1 or BA.2 breakthrough infection, nor across different variants (ancestral 224 vs Omicron) (Table S4), we pooled neutralisation data for all subjects across all 225 variants and fitted a linear mixed effects model to estimate an average decay rate of 226 880 days. Using the geometric mean peak neutralisation titres from BA.1 and BA.2 227 breakthrough infection and the global decay rate, we predict that 70% protective 228 efficacy against the homologous infecting strain would last approximately 4.5 years 229 for BA.1 breakthrough and 7 years for BA.2 breakthrough. Similarly durable 230 protective efficacy was estimated for the ancestral variant, lasting more than 8.5 and 231 10 years above 70% for BA.1 and BA.2 breakthrough respectively. Forecasting

protection to a variant to which participants had not been exposed (e.g., BA.4),
protective efficacy was predicted to be maintained above 70% for 705 and 1607
days for BA.1 and BA.2 breakthrough respectively.

235

236 Given the continued emergence of Omicron sub-lineages with additional immune 237 escape mutations, we next modelled the impact of immune evasion on the stability of 238 protection against symptomatic reinfection in a population that gained hybrid 239 immunity by Omicron BA.1 or BA.2 breakthrough infection. Notably, even at 240 timepoints where plasma neutralisation activity is maximal (~1 month post-symptom 241 onset), a novel variant with 3- or 10-fold reduction in neutralisation would reduce the 242 protective efficacy from 90.1% to 74.1% or 46.8% respectively for BA.1 hybrid 243 immune individuals, and from 95.3% to 85.5% or 63.4% respectively for BA.2 (Figure 244 4C, 4D). These fold change estimates are highly relevant, as comparable reductions 245 in neutralisation activity have already been observed with recent Omicron 246 sublineages BQ.1.1 and XBB (10). Overall, our modelling suggests that recovery 247 from an Omicron breakthrough infection confers remarkably durable protection 248 against closely related viral strains, but this protection can be rapidly subverted by 249 the emergence of novel variants with increasing escape from neutralising antibodies.

250

251 **Discussion**

252 The marked immune evasiveness and transmissibility of Omicron strains are driving 253 increasing numbers of vaccine breakthrough infections worldwide, although the 254 durability of immunity elicited by such infections remain unclear. Using intensive 255 longitudinal sampling, we find both BA.1 or BA.2 breakthrough infection drive 256 expansion of neutralising responses against the infecting strains from low or 257 undetectable levels to high titres that were stably maintained from around 1 month 258 post-symptom onset. Importantly, we show that only cross-reactive memory B cells 259 were expanded by breakthrough infection, and the resulting antibody response was 260 dominated by antibodies cross-reactive with ancestral spike, indicating that limited 261 de novo responses were generated against neo-epitopes within BA.1 or BA.2 spike.

262

263 In line with recent studies (3, 11), our results are suggestive of immune imprinting, 264 with no evident increase in BA.1 or BA.2 monospecific B cells even up to 4-7 months 265 post-infection. Interestingly, Kaku et al. reported that BA.1 breakthrough infection 266 drove affinity maturation of cross-reactive B cells and antibodies towards Omicron 267 BA.1 over time (11), although our data suggests mechanistically this occurs through 268 selective re-expansion of B cell memory. While the isolation of receptor binding 269 domain (RBD)-specific monoclonal antibodies (mAbs) specific for the BA.1 RBD that 270 do not cross-react with ancestral RBD has been reported, these comprised only a 271 small fraction (median 4%) of the response to RBD (11), confirming that neo-272 epitopes are poorly recognised during breakthrough infection. Immune imprinting is 273 not constrained to breakthrough infections, as monovalent Omicron BA.1 or bivalent 274 Beta/Delta mRNA vaccines also predominantly boost pre-existing cross-reactive 275 responses (12).

276

While superficially attractive, "overcoming" immune imprinting to generate responses against neo-epitopes may not actually be favourable for protection. Primary infection with Omicron elicits very limited neutralising breadth against historical non-Omicron variants (*13*). Similarly, Omicron-specific mAbs isolated from BA.1, BA.2 or BA.5 breakthrough individuals that do not bind ancestral RBD exhibit very narrow breadth of recognition, with little to no neutralisation activity against more recent Omicron variants including BQ.1.1 and XBB (*10*).

284

285 It remains unclear if there is something unique about "hybrid immunity" (vaccination 286 then infection) in terms of durable reprogramming of the antibody response. 287 Epidemiological studies have indicated that hybrid immunity confers stronger and 288 more durable protection against infection compared to vaccine- or infection-elicited 289 immunity alone (14-17). In line with other reports (6, 18), our data suggest that BA.1 290 and BA.2 breakthrough infection confers neutralisation breadth that extend to the 291 more immune evasive BA.4 variant. Studies of a third dose of an ancestral spike 292 vaccine have similarly demonstrated expansion of Omicron-specific B cells and 293 enhancement of neutralisation breadth (19, 20), although not to the same extent as 294 breakthrough infection with BA.1 (6). It remains to be seen whether the bivalent 295 ancestral + BA.1 or ancestral + BA.5 mRNA vaccines can elicit equivalent levels of 296 neutralisation breadth to Omicron breakthrough infection. Intriguingly, Muik et al. 297 showed that neutralisation of BA.2 and BA.4/5 mediated by BA.2 breakthrough sera 298 is highly dependent on antibodies against the N-terminal domain (NTD) of spike, 299 while BA.1 breakthrough sera-mediated neutralisation is almost exclusively 300 dependent on RBD antibodies (21). The different antibody targets elicited by BA.1 vs

301 BA.2 breakthrough infection may have implications for immunity towards future 302 Omicron variants, depending on which region of spike (RBD and/or NTD) gains 303 further escape mutations (*10*, *22*).

304

305 Both waning immunity and immune escape of new variants contribute to 306 susceptibility of SARS-CoV-2 reinfection, though the relative contribution of these 307 two factors is unknown. Here, we modelled the level of immune boosting and rate of 308 antibody waning after breakthrough infection with BA.1 and BA.2 variants. Our 309 analysis suggests robust and prolonged immunity to the homologous strain (70%) 310 protective efficacy for 4.5 and 7 years following BA.1 or BA.2 breakthrough infection). 311 However, this protection is rapidly undermined by the emergence of more escaped 312 variants. For example, a variant with a 3-fold reduction in neutralising antibody titre 313 would reduce protective efficacy by the same amount expected after 3.8 years of 314 waning immunity. A novel variant with a 10-fold reduction in neutralising antibody 315 titre would reduce protective efficacy to 46.8% and 63.4% immediately following 316 BA.1 or BA.2 breakthrough infection. This suggests that waning immunity likely plays 317 a relatively small role in the ongoing susceptibility of SARS-CoV-2, especially with 318 the emergence of BQ.1.1 (BA.5-derived) and XBB (BA.2-derived) variants that have 319 displayed 9-37 fold drops in neutralisation relative to the homologous infecting 320 strains in BA.1/BA.2 breakthrough cohorts (10, 23, 24).

321

322 Repeated, sequential waves of Omicron outbreaks have driven significant 323 breakthrough infections and conferred "hybrid" immunity to much of the global 324 population. Our data suggests that continuing spread of SARS-CoV-2 in this immune

- 325 landscape will be less a function of waning immunity and in large part depend on the
- 326 viral acquisition of further neutralisation escape mutations.

327 Materials and methods

328 Human subjects and ethics

329 A cohort of previously vaccinated participants with breakthrough COVID-19 (either 330 PCR or rapid antigen test positive) were recruited through contacts with the 331 investigators and invited to provide serial blood and nasal swab samples following 332 symptom onset (Table S1), some of whom were previously described (5). Infecting 333 variant was confirmed via whole genome sequencing of nasal swabs. For three 334 participants where early nasal swabs were not available, the infecting variant was 335 assigned based on predominant circulating strain at the time of infection. For all 336 participants, whole blood was collected with sodium heparin anticoagulant. Plasma 337 was collected and stored at -80°C, and PBMCs were isolated via Ficoll-Paque 338 separation, cryopreserved in 10% DMSO/FCS and stored in liquid nitrogen. Study 339 protocols were approved by the University of Melbourne Human Research Ethics 340 Committee (2021-21198-15398-3, 2056689), and all associated procedures were 341 carried out in accordance with approved guidelines. All participants provided written 342 informed consent in accordance with the Declaration of Helsinki.

343

344 Analysis of viral RNA load by qPCR

For viral RNA extraction, 200 µL of nasal swab sample was extracted with the QIAamp 96 Virus QIAcube HT kit (Qiagen, Germany) on the QIAcube HT System (Qiagen) according to manufacturer's instructions. Purified nucleic acid was then immediately converted to cDNA by reverse transcription with random hexamers using the SensiFAST cDNA Synthesis Kit (Bioline Reagents, UK) according to manufacturer's instructions. cDNA was used immediately in the rRT-PCR or stored at -20°C. Three microlitres of cDNA was added to a commercial real-time PCR

352 master mix (PrecisionFast qPCR Master Mix; Primer Design, UK) in a 20 µL reaction 353 mix containing primers and probe with a final concentration of 0.8µM and 0.1µM for 354 each primer and the probe, respectively. Samples were tested for the presence of 355 SARS-CoV-2 nucleocapsid (N) genes using previously described primers and 356 probes (25, 26). Thermal cycling and rRT-PCR analyses for all assays were 357 performed on the ABI 7500 FAST real-time PCR system (Applied Biosystems, USA) 358 with the following thermal cycling profile: 95°C for 2 min, followed by 45 PCR cycles 359 of 95°C for 5 s and 60°C for 30 s for N gene.

360

361 ELISA (N lgG and blocking ELISA)

362 Antibody binding to SARS-CoV-2 N protein was tested by ELISA. 96-well Maxisorp 363 plates (Thermo Fisher) were coated overnight at 4°C with 2µg/mL recombinant 364 N. After blocking with 1% FCS in PBS, duplicate wells of serially diluted plasma were 365 added and incubated for two hours at room temperature. Bound antibody was 366 detected using 1:20,000 dilution of HRP-conjugated anti-human IgG (Sigma) and 367 plates developed using TMB substrate (Sigma), stopped using sulphuric acid and 368 read at 450nm. Endpoint titres were calculated using Graphpad Prism as the 369 reciprocal serum dilution giving signal 2x background using a fitted curve (4 370 parameter log regression).

371

For blocking ELISA, plates were coated overnight with recombinant BA.1 or BA.2
spike proteins (Hexapro ectodomain (27)). Plasma samples were pre-incubated in
20µl PBS with 1µg of ancestral spike protein, or BSA control for 1 hour prior to serial
dilution in PBS+1%FCS containing 5µg/ml ancestral spike protein or BSA. Diluted

376 plasma was added to the coated plate and incubated at room temperature for 30min,

377 before washing and developing as described above.

378

379 SARS-CoV-2 virus propagation and titration

380 Ancestral SARS-CoV-2 (VIC01) isolate was grown in Vero cells in serum-free DMEM 381 with 1µg/ml TPCK trypsin while Omicron BA.1, BA.2 and BA.4 strains were grown in 382 Calu3 cells in DMEM with 2% FCS. Cell culture supernatants containing infectious 383 virus were harvested on Day 3 for VIC01 and Day 4 for Omicron strains, clarified via 384 centrifugation, filtered through a 0.45µM cellulose acetate filter and stored at -80°C. 385 Infectivity of virus stocks was then determined by titration on HAT-24 cells (a clone of 386 transduced HEK293T cells stably expressing human ACE2 and TMPRSS2 (28)). In 387 a 96-well flat bottom plate, virus stocks were serially diluted five-fold (1:5-1:78,125) 388 in DMEM with 5% FCS, added with 30,000 freshly trypsinised HAT-24 cells per well 389 and incubated at 37°C. After 46 hours, 10µl of alamarBlue™ Cell Viability Reagent 390 (ThermoFisher) was added into each well and incubated at 37°C for 1 hour. The 391 reaction was then stopped with 1% SDS and read on a FLUOstar Omega plate 392 reader (excitation wavelength 560nm, emission wavelength 590nm). The relative 393 fluorescent units (RFU) measured were used to calculate %viability ('sample' ÷ 'no 394 virus control' \times 100), which was then plotted as a sigmoidal dose response curve on 395 Graphpad Prism to obtain the virus dilution that induces 50% cell death (50% 396 infectious dose; ID_{50}). Each virus was titrated in quintuplicate in three independent 397 experiments to obtain mean ID_{50} values.

398

399 SARS-CoV-2 microneutralisation assay with viability dye readout

400 In 96-well flat bottom plates, heat-inactivated plasma samples were diluted 2.5-fold 401 (1:20-1:12,207) in duplicate and incubated with SARS-CoV-2 virus at a final 402 concentration of 2x ID₅₀ at 37°C for 1 hour. Next, 30,000 freshly trypsinised HAT-24 403 cells in DMEM with 5% FCS were added and incubated at 37°C. 'Cells only' and 404 'Virus+Cells' controls were included to represent 0% and 100% infectivity 405 respectively. After 46 hours, 10µl of alamarBlue[™] Cell Viability Reagent 406 (ThermoFisher) was added into each well and incubated at 37°C for 1 hour. The 407 reaction was then stopped with 1% SDS and read on a FLUOstar Omega plate 408 reader (excitation wavelength 560nm, emission wavelength 590nm). The relative 409 fluorescent units (RFU) measured were used to calculate %neutralisation with the 410 following formula: ('Sample' – 'Virus+Cells') \div ('Cells only' – 'Virus+Cells') \times 100. IC₅₀ 411 values were determined using four-parameter non-linear regression in GraphPad 412 Prism with curve fits constrained to have a minimum of 0% and maximum of 100% 413 neutralisation.

414

415 Flow cytometric detection of SARS-CoV-2 spike-reactive B cells

416 Biotinylated recombinant SARS-CoV-2 Spike of ancestral Wuhan Hu-1 and Omicron 417 (BA.1 or BA.2) strains were conjugated to streptavidin-APC or -PE fluorophores, 418 respectively. PBMCs were thawed and stained with Agua viability dye (Thermo 419 Fisher Scientific) and then surface stained with Spike probes, CD19 ECD (J3-119) 420 (Beckman Coulter), IgA VioBlue (IS11-8E10) IgM BUV395 (G20-127), IgD PE-Cy7 421 (IA6-2), IgG BV786 (G18-145), CD21 BUV737 (B-ly4), CD27 BV605 (O323), 422 streptavidin BV510 (BD Biosciences), CD14 BV510 (M5E2), CD3 BV510 (OKT3), 423 CD8a BV510 (RPA-T8), CD16 BV510 (3G8), and CD10 BV510 (HI10a) (BioLegend). 424 Cells were washed twice with PBS containing 1% FCS and fixed with 1%

425 formaldehyde (Polysciences) and acquired on a BD LSR Fortessa using BD FACS

426 Diva.

427

428 Modelling the kinetics of antibody recall and decay

We used a piecewise model to estimate the activation time and growth rate of various immune responses (neutralization and N IgG responses) following breakthrough infections. The model of the immune response y for subject i at time y_i can be written as:

$$y_{i}(t) = \begin{cases} (B+b_{i}); \ t \geq T_{1} + \tau_{1_{i}} \\ (B+b_{i})e^{(G+g_{i})(t-(T_{1}+\tau_{1_{i}}))}; \ T_{1} + \tau_{1_{i}} \leq t < T_{2} + \tau_{2_{i}} \\ (B+b_{i})e^{(G+g_{i})((T_{2}+\tau_{2_{i}})-(T_{1}+\tau_{1_{i}}))} \times e^{-(D+d_{i})(t-(T_{2}+\tau_{2_{i}}))}; \ t \geq T_{2} + \tau_{2_{i}}. \end{cases}$$

433 The model has 5 parameters; B, G, T_1 , D, and T_2 . For a period before T_1 , we assumed 434 a constant baseline value B for the immune response. After the activation time T_1 , 435 the immune response will grow at a rate of G until T_2 . From T_2 , the immune response 436 will decay at a rate of D. For each subject i, the parameters were taken from a 437 normal distribution, with each parameter having its own mean (fixed effect). A 438 diagonal random effect structure was used, where we assumed there was no 439 correlation within the random effects. The model was fitted to the log-transformed 440 data values, with a constant error model distributed around zero with a standard 441 deviation σ . To account for the values less than the limit of detection, a censored 442 mixed effect regression was used to fit the model. A categorical covariate was used 443 to quantify the difference in parameters between different groups (i.e. BA.1 vs BA.2 444 group), and significance was determined based on the value of this binary covariate 445 using a Wald test. Model fitting was performed using MonolixR2019b.

446

447 The decay rate of neutralisation was estimated by fitting a linear mixed effect model 448 for each response variable as a function of days post-symptom onset, infection wave 449 (i.e. BA.1 and BA.2), and response type (WT, matched, and BA.4). Likelihood ratio 450 test was used to determine if the decay rate is different with respect to infection wave 451 and response type. We fitted the model to log-transformed data of various response 452 variables (assuming exponential decay), and we censored the data from below if it 453 was less than the threshold for detection. The model was fitted by using *lmec* library 454 in R (v4.2.1), using the maximum likelihood algorithm to fit for the fixed effects.

455

456 Predicting vaccine efficacy to different variants after breakthrough infection

457 We used the previously published model for predicting vaccine efficacy for a given 458 plasma neutralisation titre (9). This model relates the neutralisation titre normalised 459 to the geometric mean neutralisation titre against ancestral virus, of a convalescent 460 cohort (individuals infected with the ancestral virus), with vaccine efficacy. Thus, we 461 first estimated the geometric mean peak neutralisation titre for BA.1 and BA.2 462 breakthrough infections against three variants (the ancestral virus, the matched 463 breakthrough variant and BA.4), and normalised these to a previously reported 464 cohort (n=8) of convalescent individuals (29) using the same neutralisation assay 465 (Geometric mean neutralisation titre of this cohort 507.6). Pooling the data on the 466 decay of neutralisation across all individuals and variants we estimated the kinetics 467 of neutralisation against each of these variants up to 3650 days after the peak. 468 These predicted kinetics of neutralisation titres were then used in the model by 469 Khoury et al. to predict vaccine efficacy at each neutralisation titre using the formula:

$$VE(n(t)) = \int_{-\infty}^{\infty} N(x : \log_{10}(n(t)), \sigma) \frac{1}{1 + e^{-k \cdot (x - x_{50})}} dx$$

471 where $N(x : \mu, \alpha)$ is the probability density function of a normal distribution with 472 mean μ and standard deviation α , σ is the standard deviation of log₁₀ neutralisation 473 titres of the vaccinated population, n(t) is the geometric mean neutralisation titre at 474 time t days after the peak neutralisation titre (normalised to the geometric mean of 475 the convalescent cohort), and x_{50} is the log₁₀ neutralisation titre associated with 50% 476 protection. The parameters σ , k and x_{50} were estimated in Khoury et al. along with 477 standard errors of the parameter estimates (9). Confidence intervals of the 478 predictions were estimated by parametric bootstrapping as described previously (30). 479 In brief, 10,000 random samples of the estimated peak neutralisation titre, decay rate, 480 and model parameters σ , k and x_{50} were randomly drawn from normal distributions 481 around the mean estimates of each parameter using the standard error of each 482 estimate or covariance matrix where appropriate, the VE was estimated using the above equation for each set of sampled parameters and the 2.5th and 97.5th 483 484 percentiles of the bootstrapped estimates at each neutralisation titre were calculated 485 as the lower and upper 95% confidence bounds, respectively (indicated by shaded 486 region in figure 4).

488 **References**

- 489 1. H. Tegally, M. Moir, J. Everatt, M. Giovanetti, C. Scheepers, E. Wilkinson, K. 490 Subramoney, Z. Makatini, S. Moyo, D. G. Amoako, C. Baxter, C. L. Althaus, U. 491 J. Anyaneji, D. Kekana, R. Viana, J. Giandhari, R. J. Lessells, T. Maponga, D. 492 Maruapula, W. Choga, M. Matshaba, M. B. Mbulawa, N. Msomi, N.-S. 493 consortium, Y. Naidoo, S. Pillay, T. J. Sanko, J. E. San, L. Scott, L. Singh, N. 494 A. Magini, P. Smith-Lawrence, W. Stevens, G. Dor, D. Tshiabuila, N. Wolter, 495 W. Preiser, F. K. Treurnicht, M. Venter, G. Chiloane, C. McIntyre, A. O'Toole, 496 C. Ruis, T. P. Peacock, C. Roemer, S. L. Kosakovsky Pond, C. Williamson, O. 497 G. Pybus, J. N. Bhiman, A. Glass, D. P. Martin, B. Jackson, A. Rambaut, O. 498 Laguda-Akingba, S. Gaseitsiwe, A. von Gottberg, T. de Oliveira, Emergence 499 of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med 28, 500 1785-1790 (2022).
- N. P. Hachmann, J. Miller, A. Y. Collier, J. D. Ventura, J. Yu, M. Rowe, E. A.
 Bondzie, O. Powers, N. Surve, K. Hall, D. H. Barouch, Neutralization Escape
 by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. *N Engl J Med* 387, 86-88 (2022).
- J. Quandt, A. Muik, N. Salisch, B. G. Lui, S. Lutz, K. Kruger, A. K. Wallisch, P. Adams-Quack, M. Bacher, A. Finlayson, O. Ozhelvaci, I. Vogler, K. Grikscheit, S. Hoehl, U. Goetsch, S. Ciesek, O. Tureci, U. Sahin, Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. *Sci Immunol* **7**, eabq2427 (2022).
- 510 4. C. I. Kaku, A. J. Bergeron, C. Ahlm, J. Normark, M. Sakharkar, M. N. E.
 511 Forsell, L. M. Walker, Recall of preexisting cross-reactive B cell memory after
 512 Omicron BA.1 breakthrough infection. *Sci Immunol* 7, eabq3511 (2022).
- M. Koutsakos, W. S. Lee, A. Reynaldi, H. X. Tan, G. Gare, P. Kinsella, K. C.
 Liew, G. Taiaroa, D. A. Williamson, H. E. Kent, E. Stadler, D. Cromer, D. S.
 Khoury, A. K. Wheatley, J. A. Juno, M. P. Davenport, S. J. Kent, The
 magnitude and timing of recalled immunity after breakthrough infection is
 shaped by SARS-CoV-2 variants. *Immunity* 55, 1316-1326 e1314 (2022).
- 518 6. W. Wang, S. Lusvarghi, R. Subramanian, N. J. Epsi, R. Wang, E. Goguet, A. 519 C. Fries, F. Echegaray, R. Vassell, S. A. Coggins, S. A. Richard, D. A. Lindholm, K. Mende, E. C. Ewers, D. T. Larson, R. E. Colombo, C. J. 520 Colombo, J. O. Joseph, J. S. Rozman, A. Smith, T. Lalani, C. M. Berjohn, R. 521 522 C. Maves, M. U. Jones, R. Mody, N. Huprikar, J. Livezey, D. Saunders, M. 523 Hollis-Perry, G. Wang, A. Ganesan, M. P. Simons, C. C. Broder, D. R. Tribble, 524 E. D. Laing, B. K. Agan, T. H. Burgess, E. Mitre, S. D. Pollett, L. C. Katzelnick, 525 C. D. Weiss, Antigenic cartography of well-characterized human sera shows 526 SARS-CoV-2 neutralization differences based on infection and vaccination 527 history. Cell Host Microbe 30, 1745-1758 e1747 (2022).

- 528 7. O. Puhach, K. Adea, N. Hulo, P. Sattonnet, C. Genecand, A. Iten, F.
 529 Jacquerioz, L. Kaiser, P. Vetter, I. Eckerle, B. Meyer, Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or 531 Omicron SARS-CoV-2. *Nat Med* 28, 1491-1500 (2022).
- 8. T. C. Bouton, J. Atarere, J. Turcinovic, S. Seitz, C. Sher-Jan, M. Gilbert, L.
 White, Z. Zhou, M. M. Hossain, V. Overbeck, L. Doucette-Stamm, J. Platt, H.
 E. Landsberg, D. H. Hamer, C. Klapperich, K. R. Jacobson, J. H. Connor,
 Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications
 for timing of release from isolation: a longitudinal cohort study. *Clin Infect Dis*,
 (2022).
- 538 9. D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A.
 539 Juno, K. Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing
 540 antibody levels are highly predictive of immune protection from symptomatic
 541 SARS-CoV-2 infection. *Nat Med* 27, 1205-1211 (2021).
- Y. Cao, F. Jian, J. Wang, Y. Yu, W. Song, A. Yisimayi, J. Wang, R. An, X.
 Chen, N. Zhang, Y. Wang, P. Wang, L. Zhao, H. Sun, L. Yu, S. Yang, X. Niu,
 T. Xiao, Q. Gu, F. Shao, X. Hao, Y. Xu, R. Jin, Z. Shen, Y. Wang, X. S. Xie,
 Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD
 evolution. *bioRxiv*, 2022.2009.2015.507787 (2022).
- 547 11. C. I. Kaku, T. N. Starr, P. Zhou, H. L. Dugan, P. Khalife, G. Song, E. R.
 548 Champney, D. W. Mielcarz, J. C. Geoghegan, D. R. Burton, R. Andrabi, J. D.
 549 Bloom, L. M. Walker, Evolution of antibody immunity following Omicron BA.1
 550 breakthrough infection. *bioRxiv*, (2022).
- W. B. Alsoussi, S. K. Malladi, J. Q. Zhou, Z. Liu, B. Ying, W. Kim, A. J.
 Schmitz, T. Lei, S. C. Horvath, A. J. Sturtz, K. M. McIntire, B. Evavold, F. Han,
 S. M. Scheaffer, I. F. Fox, L. Parra-Rodriguez, R. Nachbagauer, B. Nestorova,
 S. Chalkias, C. W. Farnsworth, M. K. Klebert, I. Pusic, B. S. Strnad, W. D.
 Middleton, S. A. Teefey, S. P. J. Whelan, M. S. Diamond, R. Paris, J. A.
 O'Halloran, R. M. Presti, J. S. Turner, A. H. Ellebedy, SARS-CoV-2 Omicron
 boosting induces de novo B cell response in humans. *bioRxiv*, (2022).
- 558 13. R. K. Suryawanshi, I. P. Chen, T. Ma, A. M. Syed, N. Brazer, P. Saldhi, C. R. 559 Simoneau, A. Ciling, M. M. Khalid, B. Sreekumar, P. Y. Chen, G. R. Kumar, M. 560 Montano, R. Gascon, C. L. Tsou, M. A. Garcia-Knight, A. Sotomayor-561 Gonzalez, V. Servellita, A. Gliwa, J. Nguyen, I. Silva, B. Milbes, N. Kojima, V. 562 Hess, M. Shacreaw, L. Lopez, M. Brobeck, F. Turner, F. W. Soveg, A. F. 563 George, X. Fang, M. Maishan, M. Matthay, M. K. Morris, D. Wadford, C. 564 Hanson, W. C. Greene, R. Andino, L. Spraggon, N. R. Roan, C. Y. Chiu, J. A. 565 Doudna, M. Ott, Limited cross-variant immunity from SARS-CoV-2 Omicron 566 without vaccination. Nature 607, 351-355 (2022).
- 567 14. S. P. Andeweg, B. de Gier, D. Eggink, C. van den Ende, N. van Maarseveen,
 568 L. Ali, B. Vlaemynck, R. Schepers, S. J. M. Hahne, C. Reusken, H. E. de

- 569 Melker, S. van den Hof, M. J. Knol, Protection of COVID-19 vaccination and 570 previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 571 infections. *Nat Commun* **13**, 4738 (2022).
- H. N. Altarawneh, H. Chemaitelly, H. H. Ayoub, P. Tang, M. R. Hasan, H. M. Yassine, H. A. Al-Khatib, M. K. Smatti, P. Coyle, Z. Al-Kanaani, E. Al-Kuwari, A. Jeremijenko, A. H. Kaleeckal, A. N. Latif, R. M. Shaik, H. F. Abdul-Rahim, G. K. Nasrallah, M. G. Al-Kuwari, A. A. Butt, H. E. Al-Romaihi, M. H. Al-Thani, A. Al-Khal, R. Bertollini, L. J. Abu-Raddad, Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. *N Engl J Med* 387, 21-34 (2022).
- A. A. Powell, F. Kirsebom, J. Stowe, M. E. Ramsay, J. Lopez-Bernal, N.
 Andrews, S. N. Ladhani, Protection against symptomatic infection with delta
 (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants
 after previous infection and vaccination in adolescents in England, August,
 2021-March, 2022: a national, observational, test-negative, case-control study. *Lancet Infect Dis*, (2022).
- N. Bobrovitz, H. Ware, X. Ma, Z. Li, R. Hosseini, C. Cao, A. Selemon, M.
 Whelan, Z. Premji, H. Issa, B. Cheng, L. J. A. Raddad, D. Buckeridge, M. Van Kerkhove, V. Piechotta, M. Higdon, A. Wilder-Smith, I. Bergeri, D. Feikin, R. K.
 Arora, M. Patel, L. Subissi, Protective effectiveness of prior SARS-CoV-2 infection and hybrid immunity against Omicron infection and severe disease: a systematic review and meta-regression. *medRxiv*, 2022.2010.2002.22280610 (2022).
- 592 18. C. Graham, T. Lechmere, A. Rehman, J. Seow, A. Kurshan, I. Huettner, T. J.
 593 A. Maguire, J. C. H. Tam, D. Cox, C. Ward, M. Racz, A. Waters, C. Mant, M.
 594 H. Malim, J. Fox, K. J. Doores, The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against 596 SARS-CoV-2 variants of concern. *PLoS Pathog* 18, e1010882 (2022).
- F. Muecksch, Z. Wang, A. Cho, C. Gaebler, T. Ben Tanfous, J. DaSilva, E. Bednarski, V. Ramos, S. Zong, B. Johnson, R. Raspe, D. Schaefer-Babajew, I. Shimeliovich, M. Daga, K. H. Yao, F. Schmidt, K. G. Millard, M. Turroja, M. Jankovic, T. Y. Oliveira, A. Gazumyan, M. Caskey, T. Hatziioannou, P. D. Bieniasz, M. C. Nussenzweig, Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. *Nature* 607, 128-134 (2022).
- R. R. Goel, M. M. Painter, K. A. Lundgreen, S. A. Apostolidis, A. E. Baxter, J.
 R. Giles, D. Mathew, A. Pattekar, A. Reynaldi, D. S. Khoury, S. Gouma, P.
 Hicks, S. Dysinger, A. Hicks, H. Sharma, S. Herring, S. Korte, W. Kc, D. A.
 Oldridge, R. I. Erickson, M. E. Weirick, C. M. McAllister, M. Awofolaju, N.
 Tanenbaum, J. Dougherty, S. Long, K. D'Andrea, J. T. Hamilton, M.
 McLaughlin, J. C. Williams, S. Adamski, O. Kuthuru, E. M. Drapeau, M. P.
 Davenport, S. E. Hensley, P. Bates, A. R. Greenplate, E. J. Wherry, Efficient

- 610 recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 611 mRNA vaccine. *Cell* **185**, 1875-1887 e1878 (2022).
- A. Muik, B. G. Lui, M. Bacher, A. K. Wallisch, A. Toker, A. Finlayson, K.
 Kruger, O. Ozhelvaci, K. Grikscheit, S. Hoehl, S. Ciesek, O. Tureci, U. Sahin,
 Omicron BA.2 breakthrough infection enhances cross-neutralization of
 BA.2.12.1 and BA.4/BA.5. *Sci Immunol* 7, eade2283 (2022).
- Y. Cao, W. Song, L. Wang, P. Liu, C. Yue, F. Jian, Y. Yu, A. Yisimayi, P.
 Wang, Y. Wang, Q. Zhu, J. Deng, W. Fu, L. Yu, N. Zhang, J. Wang, T. Xiao,
 R. An, J. Wang, L. Liu, S. Yang, X. Niu, Q. Gu, F. Shao, X. Hao, B. Meng, R.
 K. Gupta, R. Jin, Y. Wang, X. S. Xie, X. Wang, Characterization of the
 enhanced infectivity and antibody evasion of Omicron BA.2.75. *Cell Host Microbe* **30**, 1527-1539 e1525 (2022).
- R. Uraki, M. Ito, Y. Furusawa, S. Yamayoshi, K. Iwatsuki-Horimoto, E. Adachi,
 M. Saito, M. Koga, T. Tsutsumi, S. Yamamoto, A. Otani, M. Kiso, Y. Sakai-Tagawa, H. Ueki, H. Yotsuyanagi, M. Imai, Y. Kawaoka, Humoral immune
 evasion of the omicron subvariants BQ.1.1 and XBB. *Lancet Infect Dis*, (2022).
- M. Hoffmann, G. M. N. Behrens, P. Arora, A. Kempf, I. Nehlmeier, A.
 Cossmann, L. Manthey, A. Dopfer-Jablonka, S. Pohlmann, Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation. *Lancet Infect Dis*, (2022).
- V. M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D. K. Chu, T. Bleicker, S. Brunink, J. Schneider, M. L. Schmidt, D. G. Mulders, B. L. Haagmans, B. van der Veer, S. van den Brink, L. Wijsman, G. Goderski, J. L. Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C. Reusken, M. P. Koopmans, C. Drosten, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25, (2020).
- J. F. Chan, C. C. Yip, K. K. To, T. H. Tang, S. C. Wong, K. H. Leung, A. Y.
 Fung, A. C. Ng, Z. Zou, H. W. Tsoi, G. K. Choi, A. R. Tam, V. C. Cheng, K. H.
 Chan, O. T. Tsang, K. Y. Yuen, Improved Molecular Diagnosis of COVID-19
 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time
 Reverse Transcription-PCR Assay Validated In Vitro and with Clinical
 Specimens. *J Clin Microbiol* 58, (2020).
- C. L. Hsieh, J. A. Goldsmith, J. M. Schaub, A. M. DiVenere, H. C. Kuo, K.
 Javanmardi, K. C. Le, D. Wrapp, A. G. Lee, Y. Liu, C. W. Chou, P. O. Byrne,
 C. K. Hjorth, N. V. Johnson, J. Ludes-Meyers, A. W. Nguyen, J. Park, N.
 Wang, D. Amengor, J. J. Lavinder, G. C. Ippolito, J. A. Maynard, I. J.
 Finkelstein, J. S. McLellan, Structure-based design of prefusion-stabilized
 SARS-CoV-2 spikes. *Science* **369**, 1501-1505 (2020).

- F. Tea, A. Ospina Stella, A. Aggarwal, D. Ross Darley, D. Pilli, D. Vitale, V.
 Merheb, F. X. Z. Lee, P. Cunningham, G. J. Walker, C. Fichter, D. A. Brown,
 W. D. Rawlinson, S. R. Isaacs, V. Mathivanan, M. Hoffmann, S. Pohlman, O.
 Mazigi, D. Christ, D. E. Dwyer, R. J. Rockett, V. Sintchenko, V. C. Hoad, D. O.
 Irving, G. J. Dore, I. B. Gosbell, A. D. Kelleher, G. V. Matthews, F. Brilot, S. G.
 Turville, SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and
 evasion by emerging viral variants. *PLoS Med* 18, e1003656 (2021).
- J. A. Juno, H. X. Tan, W. S. Lee, A. Reynaldi, H. G. Kelly, K. Wragg, R. Esterbauer, H. E. Kent, C. J. Batten, F. L. Mordant, N. A. Gherardin, P. Pymm, M. H. Dietrich, N. E. Scott, W. H. Tham, D. I. Godfrey, K. Subbarao, M. P. Davenport, S. J. Kent, A. K. Wheatley, Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. *Nat Med* 26, 1428-1434 (2020).
- B. Cromer, M. Steain, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, S.
 J. Kent, J. A. Triccas, D. S. Khoury, M. P. Davenport, Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *Lancet Microbe* 3, e52-e61 (2022).

667

668 Acknowledgements

- 669 We thank the participants for the generous involvement and provision of samples. 670 We thank Grace Gare and Andrew Kelly (University of Melbourne) for excellent 671 technical assistance. We thank molecular staff at the Victorian Infectious Diseases 672 Reference Laboratory for performing RT-PCR. We thank Dr Julian Druce and Dr 673 Leon Caly at the Victorian Infectious Diseases Reference Laboratory for isolating 674 and distributing SARS-CoV-2 virus isolates. We acknowledge the Melbourne 675 Cytometry Platform for provision of flow cytometry services. 676 677 Author contributions 678 Conceptualization: WSL, HXT, JAJ, SJK, AKW 679 Formal Analysis: WSL, HXT, AR, DC, MPD, DSK, AKW 680 Funding Acquisition: MPD, SJK, AKW 681 Investigation: WSL, HXT, RE, MK, JN, TA, HEK, GT, PK, KCL, TT, AKW 682 Methodology: WSL, HXT, AR, AA, SGT, DSK, AKW
- 683 Resources: GT, PK, KCL, TT, AA, SGT, DAW
- 684 Supervision: DC, MPD, SJK, JAJ, DSK, AKW
- 685 Writing original draft: WSL, HXT, AKW
- 686 Writing review & editing: WSL, HXT, RE, MK, GT, DAW, MPD, SJK, JAJ, DSK,
- 687 AKW
- 688
- 689 Funding
- 690 Australian National Health and Medical Research Council grants 1149990, 1162760
- 691 and 2004398
- Australian Medical Research Future Fund grants 2005544 and 2013870

- 693 The Victorian Government
- 694 Australian National Health and Medical Research Council Investigator or Fellowship
- 695 grants (HXT, MK, DAW, MPD, SJK, JAJ, AKW)
- 696 Melbourne Postdoctoral Fellowship (WSL)
- 697
- 698 Competing interests
- 699 The authors declare no competing interests.
- 700
- 701 Data and materials availability
- All data are available in the main text or the supplementary materials.

704 Figures



705

Figure 1. Viral load kinetics and seroconversion to N following Omicron BA.1
and BA.2 breakthrough infection. (A) Schematic of longitudinal sample collection
following breakthrough infection of vaccinated individuals with Omicron BA.1 (n=10)
or BA.2 (n=16). Each line represents a single subject, and each point represents a
sample collection (blue, nasal swab; red, blood; purple, both nasal swab and blood).
(B) Kinetics of SARS-CoV-2 viral load in nasal swabs measured by qPCR of the
nucleocapsid (N) gene. (C) Kinetics of plasma IgG titres against SARS-CoV-2

- 713 nucleocapsid (N) following breakthrough infection with BA.1 (red) or BA.2 (blue).
- 714 Subjects with previous SARS-CoV-2 infection are depicted in closed circles. The
- thick lines represent the mean estimate from the piecewise linear regression model
- 716 using the estimated parameters.



Figure 2. Omicron BA.1 and BA.2 breakthrough infection rapidly recalls
 neutralising antibodies that are broad and durable. (A) Kinetics of plasma
 neutralisation activity following breakthrough infection against ancestral VIC01 or

722 matched infecting Omicron BA.1 and BA.2 strains. Thick lines represent the mean 723 estimate from the piecewise linear regression model using the estimated parameters. 724 Plasma neutralisation activity was measured using a live virus neutralisation assav 725 against SARS-CoV-2 clinical isolates in HEK293T cells transduced with ACE2 and 726 TMPRSS2. (B) Neutralisation mediated by BA.1 and BA.2 breakthrough plasma 727 against ancestral VIC01, Omicron BA.1, BA.2 and BA.4 strains at a median of 34 728 days post-symptom onset. Data are presented as median ± IQR. (C) Longitudinal 729 decay kinetics of plasma neutralisation activity following breakthrough infection 730 against ancestral VIC01 or matched infecting Omicron BA.1 or BA.2 strains up to 4-7 731 months post-symptom onset. The best fit decay slopes (thick lines) are depicted. (D) 732 IgG antibody endpoint titres against BA.1 spike for BA.1 breakthrough subjects (red) 733 and against BA.2 spike for BA.2 breakthrough subjects (blue) following pre-734 incubation with BSA control (closed circles) or ancestral Wuhan-hu-1 spike (open 735 circles).



Figure 3. Omicron BA.1 and BA.2 breakthrough infection primarily recalls
 memory B cells that are cross-reactive against ancestral spike.

740	(A) Representative flow cytometry plots of memory B cells (CD19+ IgD-) stained with
741	ancestral (Wuhan Hu-1) and BA.1 or BA.2 fluorescent spike probes, from two
742	individuals with BA.1 breakthrough infection and two with BA.2 breakthrough
743	infection at around day 10 and 30 post-symptom onset. (B) Frequencies of memory
744	B cells (CD19+ IgD-) from BA.1 breakthrough subjects (red) and BA.2 breakthrough
745	subjects (blue) that are cross-reactive with Wuhan Hu-1 and BA.1/BA.2 spike (top) or
746	memory B cells that only recognise BA.1/BA.2 spike (bottom) over time. (C)
747	Frequencies of activated memory B cells (CD21- CD27+) that are cross-reactive or
748	specific for BA.1/BA.2 spike from BA.1 breakthrough subjects (red) and BA.2
749	breakthrough subjects (blue). (D) Antibody isotype distribution of cross-reactive or
750	BA.1/BA.2 spike-monospecific memory B cells.









769

Figure S1. Gating strategy for the detection and phenotyping of spike-specific
B cells. Lymphocytes were identified by FSC-A vs SSC-A gating, followed by
doublet exclusion (FSC-A vs FSC-H), and gating on live CD19+ B cells. Classswitched B cells were identified as IgD-. Binding to SARS-CoV-2 ancestral Wuhan
Hu-1 or Omicron (BA.1 or BA.2) spike was assessed. Cross-reactive (Wuhan Hu-1+
Omicron+) or mono-specific (Omicron+) B cells were assessed for surface IgM, IgG
or IgA isotypes, and CD21 and CD27 co-expression.

Subject	Gender	Breakthrough infection strain	Vaccination/infection history	No. of prior vaccinations and/or infections	Last vaccine to symptom onset (days)	Acute longitudinal sampling (Fig 1B,1C, 2A)	MBC analysis (Fig 3)	Decay analysis (Fig 2C)
COR015	F	BA.1	3× BNT162b2	3	38			
COR032	F	BA.1	2× ChAdOx1 nCoV-19, 1× mRNA-1273	3	32			
CP110	М	BA.1	2× BNT162b2	2	84			
CP111	М	BA.1	2× BNT162b2	2	100			
CP112	F	BA.1	2× BNT162b2	2	90			
COR198	F	BA.1	2× ChAdOx1 nCoV-19, 1× mRNA-1273	3	39			
CP069	F	BA.1	Infection (Wuhan), 2x BNT162b2	3	111			
COR005	М	BA.1	1× NVX-CoV2373, 2× BNT162b2	3	102			
COR012	F	BA.1*	3× BNT162b2	3	38			
COR036	F	BA.2	2× BNT162b2, 1× mRNA-1273	3	90			
COR274	F	BA.2	2× ChAdOx1 nCoV-19, 1× mRNA-1273	3	155			
COR275	М	BA.2	2× ChAdOx1 nCoV-19, 1× mRNA-1273	3	83			
COR291	М	BA.2	3× BNT162b2	3	124			
COR039	F	BA.2	2× BNT162b2, 1 × mRNA-1273	3	169			
COR215	F	BA.2	2× ChAdOx1 nCoV-19, 1× mRNA-1273	3	125			
COR216	М	BA.2	2× ChAdOx1 nCoV-19,	3	122			

Supplementary Table 1. Breakthrough infection cohort demographics

	1		1				
		1× mRNA-1273					
F	BA.2	3× BNT162b2	3	151			
F	BA.2	2× ChAdOx1 nCoV-19, 1× mRNA-1273	3	64			
М	BA.2	2× ChAdOx1 nCoV-19, 1× mRNA-1273	3	85			
М	BA.2	3× BNT162b2	3	52			
F	BA.2	3× BNT162b2	3	118			
М	BA.2	2× ChAdOx1 nCoV-19, 1× mRNA-1273	3	100			
F	BA.2	2× BNT162b2, 1× mRNA-1273	3	86			
М	BA.2	Infection (Wuhan), 2× ChAdOx1 nCoV-19, 1× BNT162b2	4	49			
F	BA.2*	3× BNT162b2	3	125			
М	BA.2*	3× BNT162b2	3	157			
	F M M F M F M F M	F BA.2 F BA.2 M BA.2 M BA.2 M BA.2 M BA.2 F BA.2 M BA.2 F BA.2 M BA.2 F BA.2 F BA.2 F BA.2 F BA.2 M BA.2 M BA.2 M BA.2	Ix mRNA-1273 F BA.2 3x BNT162b2 F BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 M BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 M BA.2 3x BNT162b2 F BA.2 3x BNT162b2 F BA.2 3x BNT162b2 F BA.2 3x BNT162b2 F BA.2 3x BNT162b2 M BA.2 3x BNT162b2 M BA.2 3x BNT162b2 M BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 F BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 M BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 M BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 M BA.2 3x BNT162b2, 1x mRNA-1273 M BA.2* 3x BNT162b2	Ix mRNA-1273 Ix mRNA-1273 F BA.2 3x BNT162b2 3 F BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 3 M BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 3 M BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 3 M BA.2 3x BNT162b2 3 M BA.2 3x BNT162b2 3 F BA.2 3x BNT162b2 3 F BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 3 M BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 4 M BA.2 3x BNT162b2 3 M BA.2* 3x BNT162b2 3	Ix mRNA-1273 Image: marked state	Ix mRNA-1273 Image: mail of the system F BA.2 3x BNT162b2 3 151 Image: mail of the system F BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 3 64 Image: mail of the system M BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 3 85 Image: mail of the system M BA.2 3x BNT162b2 3 52 Image: mail of the system M BA.2 3x BNT162b2 3 52 Image: mail of the system M BA.2 3x BNT162b2 3 118 Image: mail of the system M BA.2 3x BNT162b2 3 100 Image: mail of the system F BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 3 86 Image: mail of the system M BA.2 2x BNT162b2, 1x mRNA-1273 3 86 Image: mail of the system M BA.2 2x ChAdOx1 nCoV-19, 1x mRNA-1273 4 49 Image: mail of the system M BA.2* 3x BNT162b2 3 125	Ix mRNA-1273 Image: Second secon

778

*Nasal swabs to determine infecting variant were unavailable, thus infecting strain was assigned by predominant circulating strain
 at the time of infection.

782 Supplementary Table 2. Piecewise linear regression parameters of N-binding IgG (with 95% CI) following BA.1 or BA.2
 783 breakthrough infection. Related to Fig 1B.

	Estimated parameter (95% CI)						
	BA.1 vs BA.2						
N IgG	BA.1	BA.2	p-value (for the difference)				
Activation time (days post onset)	7.4 (5.4 - 8.7)	6.7 (3.4 - 9.6)	0.63				
Doubling time (days)	2.4 (1.9 - 3.7)	1.5 (0.9 - 4)	0.08				
Fold change (from baseline)	9 (1.6 - 16.5)	14.5 (7.9 - 21)	0.24				

787 Supplementary Table 3. Piecewise linear regression parameters of neutralising antibodies (with 95% CI) following BA.1 or BA.2
 788 breakthrough infection. Related to Fig 2A.

789

	Estimated parameter (95% CI)								
Neutralization	BA.1 breakthrough infection			BA.2 breakthrough infection			BA.1 vs BA.2		
IC ₅₀	WT	BA.1	p-value (for the difference)	WT	BA.2	p-value (for the difference)	BA.1	BA.2	p-value (for the difference)
Activation time (days post onset)	2.3 (0.3 - 20.3)	3.1 (1.5 - 6.6)	0.82	2.3 (0.8 - 7.2)	3.6 (2.4 - 5.6)	0.55	3.1 (1.5 - 6.6)	3.6 (2.4 - 5.6)	0.78
Doubling time (days)	6.1 (3.3 - 11.3)	2.1 (1.5 - 3)	0.02	7.8 (5.4 - 11.2)	2.8 (2.3 - 3.5)	0.000013	2.1 (1.5 - 3)	2.8 (2.3 - 3.5)	0.26
Fold change (from baseline)	5.4 (2.2 - 8.7)	31 (13.7 - 48.3)	0.0078	15.6 (6.5 - 37.8)	34.7 (11.9 - 57.4)	0.0042	31 (13.7 - 48.3)	34.7 (11.9 - 57.4)	0.53

790

Supplementary Table 4. Decay rates of neutralising antibodies (with 95% CI) following BA.1 or BA.2 breakthrough infection.
 Related to Fig 2C.

793

	Estimated parameter (95% CI)								
Neutralization	BA.1 breakthrough infection			BA.2 breakthrough infection			BA.1 vs BA.2		
IC ₅₀	WT	BA.1	p-value (for the difference)	WT	BA.2	p-value (for the difference)	BA.1	BA.2	p-value (for the difference)
Half-life (days)*	182.8 (110.7 - 523.8)	333.5 (136.9 - 10000)	0.98	1216 (252.6 - 10000)	1049.7 (210.5 - 10000)	0.43	333.5 (136.9 - 10000)	1049.7 (210.5 - 10000)	0.36

794 *half-life upper limit is set to 10000 days